Tag Archives: LSD

Drug War Crumbles as 14 Cities Have Now Decriminalized Mushrooms, Other Psychedelics—Despite Prohibition

By Matt Agorist

Despite the overwhelming evidence showing that kidnapping and caging people for possessing illegal substances does nothing to prevent use and only leads to more crime and suffering, government is still hell bent on enforcing the war on drugs. Like a crack addict who needs to find his next fix, the state is unable to resist the temptation to kick in doors, shake down brown people, and ruin lives to enforce the drug war.

Instead of realizing the horrific nature of the enforcement of prohibition, many cities across the country double down on the drug war instead of admitting failure. As we can see from watching it unfold, this only leads to more suffering and more crime. Luckily, there are cities, and now entire states in other parts of the country that are taking steps to stop this violent war and the implications for such measures are only beneficial to all human kind.

Eight years ago, Colorado citizens—tired of the war on drugs and wise to the near-limitless benefits of cannabis—made US history by voting to legalize recreational marijuana. Then, in 2019, this state once again placed themselves on the right side of history as they voted to decriminalize magic mushrooms. But this was just the beginning and their momentum is spreading—faster and stronger, toward decriminalizing all plant-based psychedelics. Then, last year, the state of Oregon decriminalized all drugs.

Now, another spark has erupted, and this time it is in Michigan. In March, Hazel Park City Council voted to decriminalize psilocybin and other naturally occurring psychedelics — following the lead of municipalities across the country.

Hazel Park is the third city in Michigan to pass a resolution to decriminalize psilocybin and the fourteenth in the nation.

To be clear, these measures do not mean that mushrooms and other plants are now legal, it simply means that cops can’t make it a priority to go after folks for them and it won’t land people in jail for possession. While legalization would be the perfect result, this is most certainly a step in the right direction.

As the resolution states, “it shall be the policy of the City of Hazel Park that the investigation and arrest of persons for planting, cultivating, purchasing, transporting, distributing, engaging in practices with, or possessing Entheogenic Plants or plant compounds which are on the Federal Schedule 1 list shall be the lowest law enforcement priority.”

The resolution further stipulates that “city funds or resources shall not be used in any investigation, detention, arrest, or prosecution arising out of alleged violations of state and federal law regarding the use of Entheogenic Plants.”

“As the resolution states, entheogenic plants improve mental health and wellbeing, and connect people with nature and whatever deity they worship,” Councilmember Luke Londo, the resolution’s sponsor said in a press release. “This isn’t speculative. This is the truth, with a whole body of research to back it up.”

“It’s the plants that are going to bring us back to sanity. We’ve got to listen to their message and we’ve got to live reciprocally with nature and restore the natural order,” Susana Eager Valadez, director of the Huichol Center for Cultural Survival and Traditional Arts said after Oakland passed a similar measure in 2019.

Now, cops can try to focus on real crimes instead of kidnapping and caging people who are trying to heal themselves with a plant.

As TFTP has reported in the past, psilocybin-containing mushrooms are an enemy to the establishment who has every reason in the world to want to keep them as illegal as possible. The same goes for ayahuasca and other powerful mind-opening substances.

The United States Supreme Court has unanimously ruled in favor of the legal religious use of ayahuasca by the União do Vegetal, and the U.S. Court of Appeals for the Ninth Circuit has affirmed the Santo Daime Church’s freedom to use Ayahuasca for religious purposes. However, ayahuasca’s principally active ingredient, DMT, remains a Schedule I controlled substance, carrying a steep prison sentence.

DMT appears in trace amounts in human blood and urine, suggesting it must be produced within the body, which means the DEA literally classifies our own bodies as have no medical purpose.

Because the US government is so tyrannically far behind the times, many people have been forced to travel outside of the country to meet with Shamans in the Amazon who are skilled and knowledgeable about the substance.

One industry in particular, Big Pharma, stands to lose billions if measures like this one began to spread to other areas as mushrooms and other hallucinogens have been clinically tested to treat a wide range of problems, including depression.

E-Course: How to Grow Edible Mushrooms (Ad)

One in ten men in the US currently takes an antidepressant while 16.5 percent of women use them as well. If people can treat their depression with something that you can grow in your own home or a plant medicine from a shaman verses taking pills with side effects like homicidal ideation, the pharmaceutical industry would lose big time.

Indeed, there are mounds of evidence and studies showing the positive benefits of magic mushrooms, ayahuasca, and ibogaine.

As TFTP reported, a study, published in the scientific journal Neuropharmacology, found that clinically depressed people had increased neural responses to fearful faces one day after a psilocybin-assisted therapy session, which positively predicted positive clinical outcomes.

“Psilocybin-assisted therapy might mitigate depression by increasing emotional connection,” neuroscientist and study author Leor Roseman, a Ph.D. student at Imperial College London, explained to PsyPost.

This is almost the exact opposite of how standard anti-depressants operate, as SSRI’s typically work by creating an “emotional blunting.”

“[T]his is unlike SSRI antidepressants which are criticized for creating in many people a general emotional blunting,” noted Roseman.

“I believe that psychedelics hold a potential to cure deep psychological wounds, and I believe that by investigating their neuropsychopharmacological mechanism, we can learn to understand this potential,” explained Roseman.

The government also stands to lose if more measures like this take hold in other cities too.

As TFTP previously reported, mushrooms and psychedelics used to be widely accepted as a treatment for many ailments until government moved in to stop the expansion of human consciousness.

As MAPS points out, although first-hand accounts indicate that ibogaine is unlikely to be popular as a recreational drug, ibogaine remains classified as a Schedule I drug in the United States (it is also scheduled in Belgium and Switzerland). Yet despite its classification as a drug with a “high potential for abuse” and “no currently accepted medical use,” people who struggle with substance abuse continue to seek out international clinics or underground providers to receive ibogaine treatment.

In the 1940s, Western medicine began realizing the potential for psychedelics to treat addiction and psychiatric disorders. Tens of thousands of people were treated effectively, and psychedelic drugs were on the fast track to becoming mainstream medicine. But the beast of oppression reared its ugly head.

In 1967 and 1970, the UK and US governments cast all psychedelic substances into the pit of prohibition. People were waking up to the fact that governments intended to keep the world in a state of war, and that governments were working to keep the populace sedated under a cloak of consumerism. The collective mind expansion of that era came to a screeching halt under the boot and truncheon.

As John Vibes pointed out, a study actually confirmed the fear of authoritarians and showed they have every reason to oppose legal mushrooms. According to the study from the Psychedelic Research Group at Imperial College London, published in the journal Psychopharmacologypsychedelic mushrooms tend to make people more resistant to authority. They also found the psychedelic experience induced by these mushrooms also cause people to be more connected with nature.

“Our findings tentatively raise the possibility that given in this way, psilocybin may produce sustained changes in outlook and political perspective, here in the direction of increased nature relatedness and decreased authoritarianism,” researchers Taylor Lyons and Robin L. Carhart-Harris write in the study.

Now, as people share information globally, instantaneously, on a scale unstoppable by the state, we are resuming the advancement of medical research on psychedelic substances. Scientists are challenging the irrational classification of psychedelics as “class A” (UK) or “schedule 1” (US) substances, characterized as having no medical use and high potential for addiction. And, the recent push in Michigan is evidence of this.

While the stigma associated with mushrooms and other psychedelics has been perpetuated by those who wish to keep them illegal—to keep society in a constant state of obedient mediocrity—in reality, they are extremely safe.

In fact, a major study declared magic mushrooms to be the safest recreational drug on the planet.

Of an astonishing 120,000 participants from 50 nations, researchers for the Global Drug Survey found the percentage of those seeking emergency treatment for ingesting psilocybin-containing hallucinogenic mushrooms to comprise just 0.2 percent per 10,000 individuals.

Rates of hospitalization for alcohol and cocaine were an astounding five times higher.

“Magic mushrooms are one of the safest drugs in the world,” Global Drug Survey founder and consultant addiction psychiatrist, Adam Winstock, told the Guardian, noting the biggest risk users face is misidentification — ingesting the wrong mushroom — not from the psychedelic fungus, itself.

After decades, it appears that another brick in the wall of prohibition is beginning to crumble in the face of science and logic. There may be hope for humanity after all.

Source: The Free Thought Project

Psychedelic Medicine Is on the Rise and the Mental Health Sphere May Never Look Back

In the recent past, it was impossible to even consider the use of psychedelics in modern medicine. Throughout the 20th century, psychedelics such as LSD and psilocybin were a forbidden topic. The banning of these compounds in the United States began in the 1960s and restrictions scaled from there. Eventually, the majority of these hallucinogens were named Schedule I drugs and punishment for possession was not to be taken lightly. 

However, as science (and society) have progressed, there’s been a slow and steady adoption of plant and fungi medicine into the medical system, particularly the mental health sphere. As Michael Pollan said in his article, The Trip Treatment, “As the drug war subsides, scientists are eager to reconsider the therapeutic potential of these drugs, beginning with psilocybin.” 

Now, half a century after psychedelics were first declared illegal, they’re beginning to make a comeback with legalization on the state level in various cities around the country. In fact, the FDA and DEA are starting to approve psychedelic studies and allow researchers to examine the effects of the natural compounds on mental illness. This is a time many thought would never come. 

The mental health crisis is worse than we thought

The fact that we are seeing greater use of psychedelics in mental health is monumental, especially as the mental illness epidemic continues to sweep our globe. Right now, over 700 million people suffer from this unspoken epidemic – including anxiety, depression, PTSD, substance abuse and beyond. In fact, the global cost of depression is valued at a monumental $1T. 

The impact is devastating, from breaking families apart to suicide to poverty and more. Mental health statistics have only been exacerbated by the COVID-19 pandemic. With widespread social isolation, the loss of jobs and homes, and deaths of loved ones, cases have skyrocketed. There was a 20% increase in the use of antidepressant and anti-anxiety drugs in the U.S. during the COVID-19 quarantine. Additionally, the rate of depressive disorders quadrupled in the 2nd quarter of 2019.  

The medical sphere is coming to terms with the fact that we need better solutions. Common treatments used for these chronic conditions are outdated and not effective in providing sufficient support or long-term relief. Believe it or not, the non-adherence rate to antidepressants is 75%, meaning that the medication either doesn’t work or has a negative impact on the patient. And, nearly one-third of patients with Major Depressive Disorder (MDD) are treatment-resistant while 50-66% of patients on antidepressants do not fully recover. 

It’s time for something better – a solution that provides people with the relief they need to thrive. And for the 700 million people suffering worldwide, that can’t come soon enough. This is where natural medicine steps in. 

More and more research shows that psychedelics like psilocybin mushrooms and LSD could be effective in helping people who suffer from chronic mental health conditions. In 2018, the FDA granted “breakthrough therapy” status to psilocybin mushrooms, referring to clinical trials for the fungi to aid patients suffering from treatment-resistant depression. Due to the increasing need for innovation in the mental health sphere and growing social acceptance of psychedelics, more time and money is being put into psychedelic research for mental illness as it proves a promising solution to a growing epidemic.

Non-synthetic medicines prove promising

In a medical environment that prioritizes synthetic drugs, patients might not have access to natural and effective solutions for years to come. Fortunately, Ei.Ventures (Emotional Intelligence Ventures) is determined to shift this dismal projection. Stemming from a passion for creating natural, non-synthetic remedies for the vast number of people suffering from chronic mental health conditions, Ei.Ventures is developing botanical psychedelic therapeutics and nutraceuticals.

In a study of 2000 individuals, it was discovered that 1 in 2 people avoid traditional medicine in favor of natural alternatives because synthetic medications simply aren’t doing the trick. Ei.Ventures takes the stance in the “farma vs. pharma” debate that whole-plant medicines can be more impactful than the synthetics commonly prescribed. They believe that their non-synthetic compounds can offer patients true, long-term relief with minimal side effects. In a medical community that has rejected natural remedies up until recent years, this cutting-edge startup has the opportunity to create big waves. 

Ei.Ventures offers a suite of mental wellness products and services designed for the prevention, reversal, and management of a variety of chronic mental health disorders. Their first project is named Psilly, a transdermal patch that administers a low-dose, psilocybin-based formulation. This proprietary formulation combines high-quality psilocybin extract with other natural and complementary plant extracts. The high-tech patches are designed to make treatment significantly more convenient than other methods. This is because the patch allows the medicine to pass through the blood-brain barrier and bypass the gastrointestinal tract, providing direct delivery of active ingredients to the body. The benefits include improved patient well-being, a quick onset with consistent drug levels, and minimal side effects. 

Ei.Ventures has also developed several functional mushroom nootropics composed of psychedelic compounds made from whole botanical extracts. These products have been formulated for a variety of indicators, including cognition and immune system, energy and vitality, mood, sleep, weight loss, mental and physical optimization, and joint and muscle pain. The company’s unique formulation process allows for these nootropics to have enhanced bioavailability and greater efficacy. 

The last branch of development includes telepsychiatry and wellness app partnerships. As a company that emphasizes a natural approach over pharmaceutical prescriptions as the first step to intervention, the company seeks to facilitate greater availability of telehealth to those in need of support.

The psychedelic pharmaceutical boom is just beginning

These areas of product development come together to represent a $34.5B industry. This groundbreaking startup is stepping into an environment rich with opportunity. Plus, there hasn’t been another time in history when people have needed effective mental health solutions more. 

Additionally, Ei.Ventures has the early mover’s advantage for several reasons: Mental health conditions have been rising since COVID-19, big pharma companies like Johnson & Johnson are starting to develop psychedelic mental health treatments, and psychoactive pharmaceuticals are in the infancy stage with a high barrier to entry.

The startup is presenting a promising opportunity to invest in psychedelic medicine. They already have a foot in the door with a leadership team that holds a strong clinical, FDA, and botanical drug development background and an experienced advisory board of thought leaders spanning multiple disciplines. They also hold a robust library of intellectual property consisting of both psychedelic and non-psychoactive compounds, and an immediate go-to-market strategy that combines FDA drug pipeline development with alternative legal pathways to bring their solutions to the market. 

Their products are currently in the pre-clinical and pre-manufacturing phase of development, and they’re aiming to provide early access to the patients who need these innovative solutions the most. The company plans to achieve commercialization and licensing beginning with Psilly, advance into phase 2 trials within 18 to 24 months, achieve full FDA approval, launch their medicinal mushroom formulas into the $250B nutraceutical market, and license their proprietary formulas to other organizations. They’re also aiming to expand their unique telepsychiatry app to compliment their products for a full spectrum approach. 

Ei.Ventures recently signed an LOI with Mycotopia Therapies Inc., a biopharma company focused on the development of medical psychedelics. When a definitive agreement is reached, Mycotopia will acquire Ei.Ventures by Q1 of 2022 and merge to become PSLY.COM, a $360 Million transaction with plans to list on NASDAQ. As a joint venture, they will focus on developing fungi and plant-based psychedelic solutions. Their main goals include completing preclinical and phase 1 trials to launch Psilly into legal jurisdictions and acquire a Drug Master File with the FDA so that they can sell their formulations while protecting their IP. 

And, under this new name, the company just purchased virtual land estate in The Sandbox, an online world where players can trade NFTs through the Sandbox marketplace. In partnership with Orthogonal Thinker, PSLY.COM will make it possible for clinicians to virtually host psychedelic therapy sessions in the metaverse. Although these plans are in their early stages, they believe that this land deal will lead the way for billions of people to receive virtual access to psychedelic therapy. 

This is just the tip of the iceberg when it comes to the mental health renaissance. 

Here’s how you can join the mental health revolution

As medicine starts to turn back to the natural world and society begins to see the merit in the earth’s unaltered plant medicine, we can understand how potent these natural compounds are. Ei.Ventures is offering an investment opportunity of a lifetime as they are getting a headstart in the medicine revolution that’s quickly gaining traction. This is your opportunity to get in on the ground floor. Invest in Ei.Ventures today.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AT:

https://www.sec.gov/Archives/edgar/data/1823182/000110465921153675/tm21…

Americans Are Dropping LSD at an Increasing Rate – And Acid Use “Probably Tripled” in 2020 Alone

ELIAS MARAT
 JUL 22, 2020

As 2020 has clearly shown, life is fraught with existential dread and can often resemble a nightmare for many of us.

If it were just a matter of cabin fever resulting from the coronavirus health crisis, that would be one thing. But this year has also entailed chaos in the streets, economic instability sweeping through our families and communities, not to mention the usual madness that has been raging across the world in recent years.

And if you’ve thought of reaching for some chemicals to escape the madness, even momentarily, you’re hardly alone.

As a recent study has shown, a growing number of Americans are using LSD to escape the deep crisis that our society has found itself in. In fact, the hallucinogen’s popularity has grown exponentially in recent years.

The authors of the study have a very simple explanation for why adults – primarily millenials and Gen Xers – are dabbling or diving headlong into using hallucinogens. Simply put, the world is on fire.

“LSD is used primarily to escape. And given that the world’s on fire, people might be using it as a therapeutic mechanism,” University of Cincinnati doctoral candidate Andrew Yockey explained to Scientific American“Now that COVID’s hit, I’d guess that use has probably tripled.”

In undertaking one of the first major studies of acid dropping among adults in the U.S., the researchers examined surveys of 168,000 Americans and found that intake of LSD had risen by a shocking 56.4 percent between 2015 and 2018.

And while one might expect that it would be the youth – in this case Generation Z – that decides what the trendiest drug might be, it turns out that Gen Z isn’t so interested in the drug that helped define the hippie an psychedelic counter-cultures of the 1960s and 1970s. In fact, those aged 18 to 25 saw their LSD use decrease by 24 percent.

By a huge margin, Those who tripped the most on acid were adults with college degrees and people aged 35 to 49, whose interest in LSD skyrocketed by 223 percent in the three-year period. Meanwhile, those over 50 saw 45 percent increase while those age 26 to 34 saw an increase in LSD use by 59 percent. Those with college degrees did 70 percent more LSD.

A number of factors have boosted the popularity of the psychedelic substance, well before the current global crisis made us desperate for some form of escape. Researchers believe that one factor may have been the outcome of the 2016 presidential election, which made certain groups seek out the drug in lieu of, perhaps, escaping to Canada.

The rising popularity of microdosing is also a likely factor in the rise of LSD use. Microdosing typically involves taking one-tenth to half of a typical “trip”-sized dose as a means to reduce depression or anxiety, enhance creativity or simply sharpen the mind.

Acid has been found to have major mood-boosting effects and, like psilocybin or “magic” mushrooms, has been found to be effective in treating anxiety, depression, and certain mental illnesses.

As a psychedelic drug, however, LSD is classified as a schedule 1 substance by the federal government due to the belief that the drug is addictive, dangerous and has no medical value.

While LSD’s popularity is rising over the years it still doesn’t come close to the mid-20th century peak of acid culture, experts say.